Clinical trials: Coronary Arterial Disease (CAD)
Coronary Artery Disease
The Arterial Revascularization Therapies Study Part II.
The main objective is to compare the effectiveness of coronary stent implantation using the sirolimus-eluting Bx VELOCITY™ balloon expandable stent with that of surgery as observed in ARTS I.
- Trial name
- ARTS II (NCT00235170)
- Testing
- drug-eluting stent
- Where
- Netherlands
- Volunteers
- 607 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Evaluation of Health Economics for Noninvasive Coronary Fractional Flow Reserve Measurement Technology
To determine whether, in a Chinese population of patients presenting to Wuhan Asia Heart Hospital, Fractional Flow Reserve Derived from Coronary Computed Tomography Angiography (CT-FFR) as a default test is noninferior in terms…
- Trial name
- NCT05593120
- Testing
- CT-FFR, Routine care
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shenzhen Raysight Intelligent Medical Technology Co., Ltd.
Coronary Artery Disease
Safety and Effectiveness of Visipaque 320mg-I/ml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart
CT (computed tomography) angiography (CTA) is an examination similar to a CAT scan that uses x-rays and a contrast medium (also called dye) to visualize blood flow in arteries and veins throughout the body.
- Trial name
- NCT00335335
- Testing
- iodixanol
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- GE Healthcare
Coronary Artery Disease
A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II
The FUTURE-II study is a confirmative clinical trial for Sirolimus Target Eluting Bioresorbable Vascular Scaffold (Firesorb) after the feasibility and safety of the device has been preliminary confirmed in a small-scale…
- Trial name
- FUTURE-II (NCT02890160)
- Testing
- Firesorb, XIENCE
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Primary Prevention of Atherosclerotic Cardiovascular Disease
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c.) administered on Day 1, Day 90, and every 6 months thereafter in patients at…
- Trial name
- NCT05739383
- Testing
- Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
- Where
- 983 sites in United States, Argentina and 40 more
- Volunteers
- 14,012 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Disease
Cobalt Chromium Stent With Antiproliferative for Restenosis II Trial (COSTAR II)
The purpose of this study is to evaluate the safety and effectiveness of the investigational stent CoStar™ Paclitaxel-Eluting Coronary Stent- a reservoir based DES system in comparison to a surface coated DES stent (TAXUS™…
- Trial name
- NCT00165035
- Testing
- CoStar Paclitaxel Drug Eluting Coronary Stent System, TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent
- Where
- 2 sites in United States
- Volunteers
- 1,701 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease, Acute Coronary Syndrome
PRESSUREwire Study
The purpose of this study is to understand routine use of FFR (Fractional Flow Reserve) and alternate indices in clinical practice.
- Trial name
- NCT02935088
- Testing
- Fractional Flow Reserve
- Where
- 71 sites in United States, Austria and 13 more
- Volunteers
- 2,217 people
- Sponsor
- Abbott Medical Devices
Gout, Coronary Artery Disease
Uric Acid Study in Healthy Male Volunteers
This study is being conducted to examine the effect of AZD6140 on the levels of certain chemicals in subjects' blood and urine.
- Trial name
- NCT00738842
- Testing
- AZD6140
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care
The objective of the HeartFlow ADVANCE Registry is to evaluate utility, clinical outcomes and resource utilization of FFRCT-guided evaluation in clinically stable, symptomatic patients with coronary artery disease (CAD) in order…
- Trial name
- ADVANCE (NCT02499679)
- Volunteers
- 4,737 people
- Sponsor
- HeartFlow, Inc.
Coronary Artery Disease
e-BioMatrix PostMarket Registry
The purpose of this registry is to capture clinical data of the BioMatrix™ and BioMatrix Flex™ (Biolimus A9™-Eluting) stent systems in relation to safety and effectiveness.
- Trial name
- eBMX-PMR (NCT01289002)
- Where
- 69 sites in Austria, Czechia and 14 more
- Volunteers
- 5,652 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
Diabetes Drug Eluting Sirolimus Stent Experience in Restenosis Trial
The main objective of this study is to assess the safety and effectiveness of the Sirolimus-eluting stent CYPHERTM and/or updated version in reducing angiographic in-stent late loss in de novo native coronary lesions of diabetic…
- Trial name
- DESSERT (NCT00497172)
- Testing
- CYPHER Sirolimus-eluting stent, Bx SONIC bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Cordis US Corp.
Coronary Artery Disease
Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
To evaluate the acute safety and device procedural success of the Emerge 1.20 mm PTCA dilatation catheter when used as a pre-dilatation device in the stenotic portion of coronary arteries or bypass grafts.
- Trial name
- NCT01635881
- Testing
- Emerge™ 1.20 mm PTCA Dilatation Catheter
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Boston Scientific Corporation
Coronary Stenosis, Coronary Artery Disease
IonMAN II Trial- Early Feasibility Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System
This is a prospective, multi-center, single-arm, open-label, early feasibility study to provide preliminary evidence for the safety and efficacy of the novel IoNIR stent system
- Trial name
- NCT06071702
- Testing
- IoNIR Ridaforolimus-Eluting Coronary Stent System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Medinol Ltd.
Coronary Artery Disease
A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD
PARAMOUNT is a prospective randomized open-label trial testing the hypothesis that a personalized management strategy in symptomatic patients with suspicion of coronary artery disease (CAD), using a CT-based coronary…
- Trial name
- PARAMOUNT (NCT06713239)
- Testing
- Cleerly Labs and Cleerly ISCHEMIA
- Where
- 21 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleerly, Inc.
Coronary Artery Disease
Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination-2nd Trial
The purpose of this study is to compare pharmacokinetics between fixed-dose combination and separate combination of clopidogrel 75mg/aspirin 100mg.
- Trial name
- NCT01496261
- Testing
- Clopidogrel and Aspirin, Fixed dose combination of clopidogrel/aspirin
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Bleeding Disorder, Stroke, Ischemic
XIENCE 28 Global Study
XIENCE 28 Global Study is a prospective, single arm, multi-center, open label, non-randomized trial to further evaluate the safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of…
- Conditions
- Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic, Hematological Disease
- Trial name
- NCT03355742
- Testing
- XIENCE, DAPT
- Where
- 52 sites in Austria, Belgium and 11 more
- Volunteers
- 963 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Evaluation of the GTX™ 5126 DES Coronary Stent System in the Treatment of Patients With a Lesion in the Coronary Artery
The GTX™ Drug Eluting Coronary Stent System is intended for the treatment of patients with a lesion in the coronary artery.
- Trial name
- NCT00777842
- Testing
- GTX™ Drug Eluting Coronary Stent System
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of…
- Trial name
- EVOLVE48 (NCT03350542)
- Testing
- SYNERGY 48 mm
- Where
- 15 sites in United States, Latvia and 2 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Stable Coronary Artery Disease
A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease
The goal of this study is to find out if a drug called selatogrel (ACT-246475) can prevent platelets from binding together when administered by an injection under the skin in the thigh or in the belly.
- Trial name
- NCT03384966
- Testing
- Selatogrel
- Where
- 20 sites in United States, Canada and 6 more
- Volunteers
- 346 people
- Sponsor
- Viatris Innovation GmbH
Coronary Artery Disease, High-risk Percutaneous Coronary Intervention
Early Feasibility Study of the Supira System in Patients Undergoing HRPCI
The objective of this study is to assess the feasibility and safety of the Supira System in providing temporary cardiovascular hemodynamic support in patients undergoing HRPCI.
- Conditions
- Coronary Artery Disease, High-risk Percutaneous Coronary Intervention, Interventional Cardiology
- Trial name
- NCT06087575
- Testing
- Supira System
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Supira Medical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.